Title: SENATE BILL 741 By: Gollihare
Official Title: SENATE BILL 741 By: Gollihare
Number of Sections: 64
Source: versions - Introduced
Media Type: application/pdf
Strikethrough Detection: 15 sections found

================================================================================

Section 1:
1
STATE OF OKLAHOMA
1
2
1st Session of the 60th Legislature (2025)
2
3
3
4
4
5
5
6
AS INTRODUCED
6
7
An Act relating to the practice of pharmacy; allowing
7
pharmacist to test or screen for and initiate drug
8
therapy for minor, nonchronic health conditions;
8
specifying allowed tests; prohibiting certain test,
9
screening, and treatment; amending 59 O.S. 2021,
9

Section 2:
Section 353.1, as amended by Section 6, Chapter 288,
10
O.S.L. 2022 (59 O.S. Supp. 2024, Section 353.1),
10
which relates to definitions used in the Oklahoma
11
Pharmacy Act; modifying and adding definitions;
11
updating statutory language and references; providing
12
for codification; and providing an effective date.
12
13
13
14
14
15
BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
15
16

Section 3:
SECTION 1. NEW LAW A new section of law to be codified
16
17
in the Oklahoma Statutes as Section 353.31 of Title 59, unless there
17
18
is created a duplication in numbering, reads as follows:
18
19
A. In accordance with a standing order issued by a licensed
19
20
allopathic or osteopathic physician or by the medical director of a
20
21
county or local health department, a pharmacist may test or screen
21
22
for and initiate drug therapy for minor, nonchronic health
22
23
conditions as defined in Section 353.1 of Title 59 of the Oklahoma
23
24
Statutes.
24
Req. No. 705 Page 1
1
B. To test for minor, nonchronic health conditions under this
1
2

Section 4:
section, the pharmacist may use any test that may guide clinical
2
3
decision-making and that is:
3
4

Section 5:
1. Approved by, cleared by, or authorized under an emergency
4
5
use authorization by the United States Food and Drug Administration;
5
6
and
6
7

Section 6:
2. Waived under the federal Clinical Laboratory Improvement
7
8
Amendments of 1988 (CLIA) or deemed to be CLIA-waived for use in
8
9
patient care settings operating under a CLIA certificate.
9
10
C. A pharmacist shall not test or screen for streptococcus or
10
11
initiate drug therapy for streptococcus to individuals under six (6)
11
12
years of age.
12
13

Section 7:
SECTION 2. AMENDATORY 59 O.S. 2021, Section 353.1, as
13
14
amended by Section 6, Chapter 288, O.S.L. 2022 (59 O.S. Supp. 2024,
14
15

Section 8:
Section 353.1), is amended to read as follows:
15
16

Section 9:
Section 353.1. For the purposes of the Oklahoma Pharmacy Act:
16
17

Section 10:
1. “Accredited program” means those seminars, classes,
17
18
meetings, work projects, and other educational courses approved by
18
19
the Board State Board of Pharmacy for purposes of continuing
19
20
professional education;
20
21

Section 11:
2. “Act” means the Oklahoma Pharmacy Act;
21
22

Section 12:
3. “Administer” means the direct application of a drug, whether
22
23
by injection, inhalation, ingestion, or any other means, to the body
23
24
of a patient;
24
Req. No. 705 Page 2
1

Section 13:
4. “Assistant pharmacist” means any person presently licensed
1
2
as an assistant pharmacist in the State of Oklahoma this state by
2
3
the Board pursuant to Section 353.10 of this title and for the
3
4
purposes of the Oklahoma Pharmacy Act shall be considered the same
4
5
as a pharmacist, except where otherwise specified;
5
6

Section 14:
5. “Board” or “State Board” means the State Board of Pharmacy;
6
7

Section 15:
6. “Certify” or “certification of a prescription” means the
7
8
review of a filled prescription by a licensed pharmacist or a
8
9
licensed practitioner with dispensing authority to confirm that the
9
10
medication, labeling, and packaging of the filled prescription are
10
11
accurate and meet all requirements prescribed by state and federal
11
12
law. For the purposes of this paragraph, “licensed practitioner”
12
13
shall not include optometrists with dispensing authority;
13
14

Section 16:
7. “Chemical” means any medicinal substance, whether simple or
14
15
compound or obtained through the process of the science and art of
15
16
chemistry, whether of organic or inorganic origin;
16
17

Section 17:
8. “Compounding” means the combining, admixing, mixing,
17
18
diluting, pooling, reconstituting, or otherwise altering of a drug
18
19
or bulk drug substance to create a drug. Compounding includes the
19
20
preparation of drugs or devices in anticipation of prescription drug
20
21
orders based on routine, regularly observed prescribing patterns;
21
22

Section 18:
9. “Continuing professional education” means professional,
22
23
pharmaceutical education in the general areas of the socioeconomic
23
24
and legal aspects of health care; the properties and actions of
24
Req. No. 705 Page 3
1
drugs and dosage forms; and the etiology, characteristics, and
1
2
therapeutics of the diseased state;
2
3

Section 19:
10. “Dangerous drug”, “legend drug”, “prescription drug”, or
3
4
“Rx Only” means a drug:
4
5
a. for human use subject to 21 U.S.C. 353(b)(1), or
5
6
b. is labeled “Prescription Only”, or labeled with the
6
7
following statement: “Caution: Federal law restricts
7
8
this drug except for to use by or on the order of a
8
9
licensed veterinarian.”;
9
10

Section 20:
11. “Director” means the Executive Director of the State Board
10
11
of Pharmacy unless context clearly indicates otherwise;
11
12

Section 21:
12. “Dispense” or “dispensing” means the interpretation,
12
13
evaluation, and implementation of a prescription drug order
13
14
including the preparation and delivery of a drug or device to a
14
15
patient or a patient’s agent in a suitable container appropriately
15
16
labeled for subsequent administration to, or use by, a patient.
16
17
Dispense includes sell, distribute, leave with, give away, dispose
17
18
of, deliver, or supply;
18
19

Section 22:
13. “Dispenser” means a retail pharmacy, hospital pharmacy, a
19
20
group of chain pharmacies under common ownership and control that do
20
21
not act as a wholesale distributor, or any other person authorized
21
22
by law to dispense or administer prescription drugs, and the
22
23
affiliated warehouses or distributions of such entities under common
23
24
ownership and control that do not act as a wholesale distributor.
24
Req. No. 705 Page 4
1
For the purposes of this paragraph, “dispenser” dispenser does not
1
2
mean a person who dispenses only products to be used in animals in
2
3
accordance with 21 U.S.C. 360b(a)(5);
3
4

Section 23:
14. “Distribute” or “distribution” means the sale, purchase,
4
5
trade, delivery, handling, storage, or receipt of a product, and
5
6
does not include the dispensing of a product pursuant to a
6
7
prescription executed in accordance with 21 U.S.C. 353(b)(1) or the
7
8
dispensing of a product approved under 21 U.S.C. 360b(b); provided,
8
9
taking actual physical possession of a product or title shall not be
9
10
required;
10
11

Section 24:
15. “Doctor of Pharmacy” means a person licensed by the Board
11
12
to engage in the practice of pharmacy. The terms “pharmacist”,
12
13
“D.Ph.”, and “Doctor of Pharmacy” shall be interchangeable and shall
13
14
have the same meaning wherever they appear in the Oklahoma Statutes
14
15
and the rules promulgated by the Board;
15
16

Section 25:
16. “Drug outlet” means all manufacturers, repackagers,
16
17
outsourcing facilities, wholesale distributors, third-party
17
18
logistics providers, pharmacies, and all other facilities which are
18
19
engaged in dispensing, delivery, distribution, or storage of
19
20
dangerous drugs;
20
21

Section 26:
17. “Drugs” means all medicinal substances and preparations
21
22
recognized by the United States Pharmacopoeia Pharmacopeia and
22
23
National Formulary, or any revision thereof, and all substances and
23
24
preparations intended for external and/or internal use in the cure,
24
Req. No. 705 Page 5
1
diagnosis, mitigation, treatment, or prevention of disease in humans
1
2
or animals and all substances and preparations, other than food,
2
3
intended to affect the structure or any function of the body of a
3
4
human or animals;
4
5

Section 27:
18. “Drug sample” means a unit of a prescription drug packaged
5
6
under the authority and responsibility of the manufacturer that is
6
7
not intended to be sold and is intended to promote the sale of the
7
8
drug;
8
9

Section 28:
19. “Durable medical equipment” has the same meaning as
9
10
provided by Section 2 of this act 375.2 of this title;
10
11

Section 29:
20. “Filled prescription” means a packaged prescription
11
12
medication to which a label has been affixed which contains such
12
13
information as is required by the Oklahoma Pharmacy Act;
13
14

Section 30:
21. “Hospital” means any institution licensed as a hospital by
14
15
this state for the care and treatment of patients, or a pharmacy
15
16
operated by the Oklahoma Department of Veterans Affairs;
16
17

Section 31:
22. “Licensed practitioner” means an allopathic physician,
17
18
osteopathic physician, podiatric physician, dentist, veterinarian,
18
19
or optometrist licensed to practice and authorized to prescribe
19
20
dangerous drugs within the scope of practice of such practitioner;
20
21

Section 32:
23. “Manufacturer” or “virtual manufacturer” means with respect
21
22
to a product:
22
23
a. a person that holds an application approved under 21
23
24
U.S.C. 355 or a license issued under 42 U.S.C. 262 for
24
Req. No. 705 Page 6
1
such product, or if such product is not the subject of
1
2
an approved application or license, the person who
2
3
manufactured the product,
3
4
b. a co-licensed partner of the person described in
4
5
subparagraph a of this paragraph that obtains the
5
6
product directly from a person described in this
6
7
subparagraph or subparagraph a of this paragraph,
7
8
c. an affiliate of a person described in subparagraph a
8
9
or b of this paragraph who receives the product
9
10
directly from a person described in this subparagraph
10
11
or in subparagraph a or b of this paragraph, or
11
12
d. a person who contracts with another to manufacture a
12
13
product;
13
14

Section 33:
24. “Manufacturing” means the production, preparation,
14
15
propagation, compounding, conversion, or processing of a device or a
15
16
drug, either directly or indirectly by extraction from substances of
16
17
natural origin or independently by means of chemical or biological
17
18
synthesis and includes any packaging or repackaging of the
18
19
substances or labeling or relabeling of its container, and the
19
20
promotion and marketing of such drugs or devices. The term
20
21
“manufacturing” manufacturing also includes the preparation and
21
22
promotion of commercially available products from bulk compounds for
22
23
resale by licensed pharmacies, licensed practitioners, or other
23
24
persons;
24
Req. No. 705 Page 7
1

Section 34:
25. “Medical gas” means those gases including those in liquid
1
2
state upon which the manufacturer or distributor has placed one of
2
3
several cautions, such as “Rx Only”, in compliance with federal law;
3
4

Section 35:
26. “Medical gas order” means an order for medical gas issued
4
5
by a licensed prescriber;
5
6

Section 36:
27. “Medical gas distributor” means a person licensed to
6
7
distribute, transfer, wholesale, deliver, or sell medical gases on
7
8
drug orders to suppliers or other entities licensed to use,
8
9
administer, or distribute medical gas and may also include a patient
9
10
or ultimate user;
10
11

Section 37:
28. “Medical gas supplier” means a person who dispenses medical
11
12
gases on drug orders only to a patient or ultimate user;
12
13

Section 38:
29. “Medicine” means any drug or combination of drugs which has
13
14
the property of curing, preventing, treating, diagnosing, or
14
15
mitigating diseases, or which is used for that purpose;
15
16

Section 39:
30. “Minor, nonchronic health condition” means a typically
16
17
short-term health condition that is generally managed with
17
18
noncontrolled drug therapies, minimal treatment, or self-care, and
18
19
is limited to the following:
19
20
a. influenzas,
20
21
b. streptococcus,
21
22
c. SARS-CoV-2,
22
23
d. lice, and
23
24
24
Req. No. 705 Page 8
1
e. other emerging and existing public health threats
1
2
identified by the State Commissioner of Health if
2
3
permitted by an order, rule, or regulation;
3
4

Section 40:
31. “Nonprescription drugs” means medicines or drugs which are
4
5
sold without a prescription and which are prepackaged for use by the
5
6
consumer and labeled in accordance with the requirements of the
6
7
statutes and regulations of this state and the federal government.
7
8
Such items shall also include medical and dental supplies and
8
9
bottled or nonbulk chemicals which are sold or offered for sale to
9
10
the general public if such articles or preparations meet the
10
11
requirements of the Federal Food, Drug, and Cosmetic Act, 21
11
12
U.S.C.A., Section 321 et seq.;
12
13

Section 41:
31. 32. “Outsourcing facility” including “virtual outsourcing
13
14
facility” means a facility at one geographic location or address
14
15
that:
15
16
a. is engaged in the compounding of sterile drugs,
16
17
b. has elected to register as an outsourcing facility,
17
18
and
18
19
c. complies with all requirements of 21 U.S.C. 353b;
19
20

Section 42:
32. 33. “Package” means the smallest individual saleable unit
20
21
of product for distribution by a manufacturer or repackager that is
21
22
intended by the manufacturer for ultimate sale to the dispenser of
22
23
such product. For the purposes of this paragraph, “individual
23
24
saleable unit” means the smallest container of a product introduced
24
Req. No. 705 Page 9
1
into commerce by the manufacturer or repackager that is intended by
1
2
the manufacturer or repackager for individual sale to a dispenser;
2
3

Section 43:
33. 34. “Person” means an individual, partnership, limited
3
4
liability company, corporation, or association, unless the context
4
5
otherwise requires;
5
6

Section 44:
34. 35. “Pharmacist-in-charge” or “PIC” means the pharmacist
6
7
licensed in this state responsible for the management control of a
7
8
pharmacy and all other aspects of the practice of pharmacy in a
8
9
licensed pharmacy as defined by Section 353.18 of this title;
9
10

Section 45:
35. 36. “Pharmacy” means a place regularly licensed by the
10
11
State Board of Pharmacy in which prescriptions, drugs, medicines,
11
12
chemicals, and poisons are compounded or dispensed or such place
12
13
where pharmacists practice the profession of pharmacy, or a pharmacy
13
14
operated by the Oklahoma Department of Veterans Affairs;
14
15

Section 46:
36. 37. “Pharmacy technician”, “technician”, “Rx tech”, or
15
16
“tech” means a person issued a Technician technician permit by the
16
17
State Board of Pharmacy to assist the pharmacist and perform
17
18
nonjudgmental, technical, manipulative, non-discretionary functions
18
19
in the prescription department under the immediate and direct
19
20
supervision of a pharmacist;
20
21

Section 47:
37. 38. “Poison” means any substance which when introduced into
21
22
the body, either directly or by absorption, produces violent,
22
23
morbid, or fatal changes, or which destroys living tissue with which
23
24
such substance comes into contact;
24
Req. No. 705 Page 10
1

Section 48:
38. 39. “Practice of pharmacy” means:
1
2
a. the interpretation and evaluation of prescription
2
3
orders,
3
4
b. the compounding, dispensing, administering, and
4
5
labeling of drugs and devices, except labeling by a
5
6
manufacturer, repackager, or distributor of
6
7
nonprescription drugs and commercially packaged legend
7
8
drugs and devices,
8
9
c. the participation in drug selection and drug
9
10
utilization reviews,
10
11
d. the proper and safe storage of drugs and devices and
11
12
the maintenance of proper records thereof,
12
13
e. the responsibility for advising by counseling and
13
14
providing information, where professionally necessary
14
15
or where regulated, of therapeutic values, content,
15
16
hazards, and use of drugs and devices,
16
17
f. the offering or performing of those acts, services,
17
18
operations, or transactions necessary in the conduct,
18
19
operation, management, and control of a pharmacy, or
19
20
g. the ordering, performing, and interpreting of tests
20
21
for minor, nonchronic health conditions that meet the
21
22
requirements of Section 1 of this act and the
22
23
initiation of drug therapy for minor, nonchronic
23
24
health conditions, or
24
Req. No. 705 Page 11
1
h. the provision of those acts or services that are
1
2
necessary to provide pharmaceutical care;
2
3

Section 49:
39. 40. “Preparation” means an article which may or may not
3
4
contain sterile products compounded in a licensed pharmacy pursuant
4
5
to the order of a licensed prescriber;
5
6

Section 50:
40. 41. “Prescriber” means a person licensed in this state who
6
7
is authorized to prescribe dangerous drugs within the scope of
7
8
practice of the person’s profession;
8
9

Section 51:
41. 42. “Prescription” means and includes any order for drug or
9
10
medical supplies written or signed, or transmitted by word of mouth,
10
11
telephone, or other means of communication:
11
12
a. by a licensed prescriber,
12
13
b. under the supervision of an Oklahoma licensed
13
14
practitioner, an Oklahoma licensed advanced practice
14
15
registered nurse Advanced Practice Registered Nurse,
15
16
or an Oklahoma licensed physician assistant, or
16
17
c. by an Oklahoma licensed wholesaler or distributor as
17
18
authorized in Section 353.29.1 of this title;
18
19

Section 52:
42. 43. “Product” means a prescription drug in a finished
19
20
dosage form for administration to a patient without substantial
20
21
further manufacturing, such as capsules, tablets, and lyophilized
21
22
products before reconstitution. “Product” Product does not include
22
23
blood components intended for transfusion, radioactive drugs or
23
24
biologics and medical gas;
24
Req. No. 705 Page 12
1

Section 53:
43. 44. “Repackager”, including “virtual repackager”, means a
1
2
person who owns or operates an establishment that repacks and
2
3
relabels a product or package for further sale or distribution
3
4
without further transaction;
4
5

Section 54:
44. 45. “Sterile drug” means a drug that is intended for
5
6
parenteral administration, an ophthalmic or oral inhalation drug in
6
7
aqueous format, or a drug that is required to be sterile under state
7
8
and federal law;
8
9

Section 55:
45. 46. “Supervising physician” means an individual holding a
9
10
current license to practice as a physician from the State Board of
10
11
Medical Licensure and Supervision, pursuant to the provisions of the
11
12
Oklahoma Allopathic Medical and Surgical Licensure and Supervision
12
13
Act, or the State Board of Osteopathic Examiners, pursuant to the
13
14
provisions of the Oklahoma Osteopathic Medicine Act, who supervises
14
15
an advanced practice registered nurse Advanced Practice Registered
15
16
Nurse as defined in Section 567.3a of this title, and who is not in
16
17
training as an intern, resident, or fellow. To be eligible to
17
18
supervise an advanced practice registered nurse Advanced Practice
18
19
Registered Nurse, such physician shall remain in compliance with the
19
20
rules promulgated by the State Board of Medical Licensure and
20
21
Supervision or the State Board of Osteopathic Examiners;
21
22

Section 56:
46. 47. “Supportive personnel” means technicians and auxiliary
22
23
supportive persons who are regularly paid employees of a pharmacy
23
24
24
Req. No. 705 Page 13
1
who work and perform tasks in the pharmacy as authorized by Section
1
2

Section 57:
353.18A of this title;
2
3

Section 58:
47. 48. “Third-party logistics provider” including “virtual
3
4
third-party logistics provider” means an entity that provides or
4
5
coordinates warehousing, or other logistics services of a product in
5
6
interstate commerce on behalf of a manufacturer, wholesale
6
7
distributor, or dispenser of a product but does not take ownership
7
8
of the product, nor have responsibility to direct the sale or
8
9
disposition of the product. For the purposes of this paragraph,
9
10
“third-party logistics provider” third-party logistics provider does
10
11
not include shippers and the United States Postal Service;
11
12

Section 59:
48. 49. “Wholesale distributor” including “virtual wholesale
12
13
distributor” means a person other than a manufacturer, a
13
14
manufacturer’s co-licensed partner, a third-party logistics
14
15
provider, or repackager engaged in wholesale distribution as defined
15
16
by 21 U.S.C. 353(e)(4) as amended by the Drug Supply Chain Security
16
17
Act;
17
18

Section 60:
49. 50. “County jail” means a facility operated by a county for
18
19
the physical detention and correction of persons charged with, or
19
20
convicted of, criminal offenses or ordinance violations or persons
20
21
found guilty of civil or criminal contempt;
21
22

Section 61:
50. 51. “State correctional facility” means a facility or
22
23
institution that houses a prisoner population under the jurisdiction
23
24
of the Department of Corrections;
24
Req. No. 705 Page 14
1

Section 62:
51. 52. “Unit dose package” means a package that contains a
1
2
single dose drug with the name, strength, control number, and
2
3
expiration date of that drug on the label; and
3
4

Section 63:
52. 53. “Unit of issue package” means a package that provides
4
5
multiple doses of the same drug, but each drug is individually
5
6
separated and includes the name, lot number, and expiration date.
6
7

Section 64:
SECTION 3. This act shall become effective November 1, 2025.
7
8
8
9
60-1-705 DC 1/19/2025 5:42:21 AM
9
10
10
11
11
12
12
13
13
14
14
15
15
16
16
17
17
18
18
19
19
20
20
21
21
22
22
23
23
24
24
Req. No. 705 Page 15
[DELETED:  P B G]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P f i]
[DELETED:  P]
[DELETED:  P a]
[DELETED:  P a a a]
[DELETED:  P i s S l]
[DELETED:  P o i h c]
[DELETED:  P]
[DELETED:  P t t t t t t t]
[DELETED:  P t b u b]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P D 1]


================================================================================

Raw Text:
1
STATE OF OKLAHOMA
1
2
1st Session of the 60th Legislature (2025)
2
3
SENATE BILL 741 By: Gollihare
3
4
4
5
5
6
AS INTRODUCED
6
7
An Act relating to the practice of pharmacy; allowing
7
pharmacist to test or screen for and initiate drug
8
therapy for minor, nonchronic health conditions;
8
specifying allowed tests; prohibiting certain test,
9
screening, and treatment; amending 59 O.S. 2021,
9
Section 353.1, as amended by Section 6, Chapter 288,
10
O.S.L. 2022 (59 O.S. Supp. 2024, Section 353.1),
10
which relates to definitions used in the Oklahoma
11
Pharmacy Act; modifying and adding definitions;
11
updating statutory language and references; providing
12
for codification; and providing an effective date.
12
13
13
14
14
15
BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
15
16
SECTION 1. NEW LAW A new section of law to be codified
16
17
in the Oklahoma Statutes as Section 353.31 of Title 59, unless there
17
18
is created a duplication in numbering, reads as follows:
18
19
A. In accordance with a standing order issued by a licensed
19
20
allopathic or osteopathic physician or by the medical director of a
20
21
county or local health department, a pharmacist may test or screen
21
22
for and initiate drug therapy for minor, nonchronic health
22
23
conditions as defined in Section 353.1 of Title 59 of the Oklahoma
23
24
Statutes.
24
Req. No. 705 Page 1

1
B. To test for minor, nonchronic health conditions under this
1
2
section, the pharmacist may use any test that may guide clinical
2
3
decision-making and that is:
3
4
1. Approved by, cleared by, or authorized under an emergency
4
5
use authorization by the United States Food and Drug Administration;
5
6
and
6
7
2. Waived under the federal Clinical Laboratory Improvement
7
8
Amendments of 1988 (CLIA) or deemed to be CLIA-waived for use in
8
9
patient care settings operating under a CLIA certificate.
9
10
C. A pharmacist shall not test or screen for streptococcus or
10
11
initiate drug therapy for streptococcus to individuals under six (6)
11
12
years of age.
12
13
SECTION 2. AMENDATORY 59 O.S. 2021, Section 353.1, as
13
14
amended by Section 6, Chapter 288, O.S.L. 2022 (59 O.S. Supp. 2024,
14
15
Section 353.1), is amended to read as follows:
15
16
Section 353.1. For the purposes of the Oklahoma Pharmacy Act:
16
17
1. “Accredited program” means those seminars, classes,
17
18
meetings, work projects, and other educational courses approved by
18
19
the Board State Board of Pharmacy for purposes of continuing
19
20
professional education;
20
21
2. “Act” means the Oklahoma Pharmacy Act;
21
22
3. “Administer” means the direct application of a drug, whether
22
23
by injection, inhalation, ingestion, or any other means, to the body
23
24
of a patient;
24
Req. No. 705 Page 2

1
4. “Assistant pharmacist” means any person presently licensed
1
2
as an assistant pharmacist in the State of Oklahoma this state by
2
3
the Board pursuant to Section 353.10 of this title and for the
3
4
purposes of the Oklahoma Pharmacy Act shall be considered the same
4
5
as a pharmacist, except where otherwise specified;
5
6
5. “Board” or “State Board” means the State Board of Pharmacy;
6
7
6. “Certify” or “certification of a prescription” means the
7
8
review of a filled prescription by a licensed pharmacist or a
8
9
licensed practitioner with dispensing authority to confirm that the
9
10
medication, labeling, and packaging of the filled prescription are
10
11
accurate and meet all requirements prescribed by state and federal
11
12
law. For the purposes of this paragraph, “licensed practitioner”
12
13
shall not include optometrists with dispensing authority;
13
14
7. “Chemical” means any medicinal substance, whether simple or
14
15
compound or obtained through the process of the science and art of
15
16
chemistry, whether of organic or inorganic origin;
16
17
8. “Compounding” means the combining, admixing, mixing,
17
18
diluting, pooling, reconstituting, or otherwise altering of a drug
18
19
or bulk drug substance to create a drug. Compounding includes the
19
20
preparation of drugs or devices in anticipation of prescription drug
20
21
orders based on routine, regularly observed prescribing patterns;
21
22
9. “Continuing professional education” means professional,
22
23
pharmaceutical education in the general areas of the socioeconomic
23
24
and legal aspects of health care; the properties and actions of
24
Req. No. 705 Page 3

1
drugs and dosage forms; and the etiology, characteristics, and
1
2
therapeutics of the diseased state;
2
3
10. “Dangerous drug”, “legend drug”, “prescription drug”, or
3
4
“Rx Only” means a drug:
4
5
a. for human use subject to 21 U.S.C. 353(b)(1), or
5
6
b. is labeled “Prescription Only”, or labeled with the
6
7
following statement: “Caution: Federal law restricts
7
8
this drug except for to use by or on the order of a
8
9
licensed veterinarian.”;
9
10
11. “Director” means the Executive Director of the State Board
10
11
of Pharmacy unless context clearly indicates otherwise;
11
12
12. “Dispense” or “dispensing” means the interpretation,
12
13
evaluation, and implementation of a prescription drug order
13
14
including the preparation and delivery of a drug or device to a
14
15
patient or a patient’s agent in a suitable container appropriately
15
16
labeled for subsequent administration to, or use by, a patient.
16
17
Dispense includes sell, distribute, leave with, give away, dispose
17
18
of, deliver, or supply;
18
19
13. “Dispenser” means a retail pharmacy, hospital pharmacy, a
19
20
group of chain pharmacies under common ownership and control that do
20
21
not act as a wholesale distributor, or any other person authorized
21
22
by law to dispense or administer prescription drugs, and the
22
23
affiliated warehouses or distributions of such entities under common
23
24
ownership and control that do not act as a wholesale distributor.
24
Req. No. 705 Page 4

1
For the purposes of this paragraph, “dispenser” dispenser does not
1
2
mean a person who dispenses only products to be used in animals in
2
3
accordance with 21 U.S.C. 360b(a)(5);
3
4
14. “Distribute” or “distribution” means the sale, purchase,
4
5
trade, delivery, handling, storage, or receipt of a product, and
5
6
does not include the dispensing of a product pursuant to a
6
7
prescription executed in accordance with 21 U.S.C. 353(b)(1) or the
7
8
dispensing of a product approved under 21 U.S.C. 360b(b); provided,
8
9
taking actual physical possession of a product or title shall not be
9
10
required;
10
11
15. “Doctor of Pharmacy” means a person licensed by the Board
11
12
to engage in the practice of pharmacy. The terms “pharmacist”,
12
13
“D.Ph.”, and “Doctor of Pharmacy” shall be interchangeable and shall
13
14
have the same meaning wherever they appear in the Oklahoma Statutes
14
15
and the rules promulgated by the Board;
15
16
16. “Drug outlet” means all manufacturers, repackagers,
16
17
outsourcing facilities, wholesale distributors, third-party
17
18
logistics providers, pharmacies, and all other facilities which are
18
19
engaged in dispensing, delivery, distribution, or storage of
19
20
dangerous drugs;
20
21
17. “Drugs” means all medicinal substances and preparations
21
22
recognized by the United States Pharmacopoeia Pharmacopeia and
22
23
National Formulary, or any revision thereof, and all substances and
23
24
preparations intended for external and/or internal use in the cure,
24
Req. No. 705 Page 5

1
diagnosis, mitigation, treatment, or prevention of disease in humans
1
2
or animals and all substances and preparations, other than food,
2
3
intended to affect the structure or any function of the body of a
3
4
human or animals;
4
5
18. “Drug sample” means a unit of a prescription drug packaged
5
6
under the authority and responsibility of the manufacturer that is
6
7
not intended to be sold and is intended to promote the sale of the
7
8
drug;
8
9
19. “Durable medical equipment” has the same meaning as
9
10
provided by Section 2 of this act 375.2 of this title;
10
11
20. “Filled prescription” means a packaged prescription
11
12
medication to which a label has been affixed which contains such
12
13
information as is required by the Oklahoma Pharmacy Act;
13
14
21. “Hospital” means any institution licensed as a hospital by
14
15
this state for the care and treatment of patients, or a pharmacy
15
16
operated by the Oklahoma Department of Veterans Affairs;
16
17
22. “Licensed practitioner” means an allopathic physician,
17
18
osteopathic physician, podiatric physician, dentist, veterinarian,
18
19
or optometrist licensed to practice and authorized to prescribe
19
20
dangerous drugs within the scope of practice of such practitioner;
20
21
23. “Manufacturer” or “virtual manufacturer” means with respect
21
22
to a product:
22
23
a. a person that holds an application approved under 21
23
24
U.S.C. 355 or a license issued under 42 U.S.C. 262 for
24
Req. No. 705 Page 6

1
such product, or if such product is not the subject of
1
2
an approved application or license, the person who
2
3
manufactured the product,
3
4
b. a co-licensed partner of the person described in
4
5
subparagraph a of this paragraph that obtains the
5
6
product directly from a person described in this
6
7
subparagraph or subparagraph a of this paragraph,
7
8
c. an affiliate of a person described in subparagraph a
8
9
or b of this paragraph who receives the product
9
10
directly from a person described in this subparagraph
10
11
or in subparagraph a or b of this paragraph, or
11
12
d. a person who contracts with another to manufacture a
12
13
product;
13
14
24. “Manufacturing” means the production, preparation,
14
15
propagation, compounding, conversion, or processing of a device or a
15
16
drug, either directly or indirectly by extraction from substances of
16
17
natural origin or independently by means of chemical or biological
17
18
synthesis and includes any packaging or repackaging of the
18
19
substances or labeling or relabeling of its container, and the
19
20
promotion and marketing of such drugs or devices. The term
20
21
“manufacturing” manufacturing also includes the preparation and
21
22
promotion of commercially available products from bulk compounds for
22
23
resale by licensed pharmacies, licensed practitioners, or other
23
24
persons;
24
Req. No. 705 Page 7

1
25. “Medical gas” means those gases including those in liquid
1
2
state upon which the manufacturer or distributor has placed one of
2
3
several cautions, such as “Rx Only”, in compliance with federal law;
3
4
26. “Medical gas order” means an order for medical gas issued
4
5
by a licensed prescriber;
5
6
27. “Medical gas distributor” means a person licensed to
6
7
distribute, transfer, wholesale, deliver, or sell medical gases on
7
8
drug orders to suppliers or other entities licensed to use,
8
9
administer, or distribute medical gas and may also include a patient
9
10
or ultimate user;
10
11
28. “Medical gas supplier” means a person who dispenses medical
11
12
gases on drug orders only to a patient or ultimate user;
12
13
29. “Medicine” means any drug or combination of drugs which has
13
14
the property of curing, preventing, treating, diagnosing, or
14
15
mitigating diseases, or which is used for that purpose;
15
16
30. “Minor, nonchronic health condition” means a typically
16
17
short-term health condition that is generally managed with
17
18
noncontrolled drug therapies, minimal treatment, or self-care, and
18
19
is limited to the following:
19
20
a. influenzas,
20
21
b. streptococcus,
21
22
c. SARS-CoV-2,
22
23
d. lice, and
23
24
24
Req. No. 705 Page 8

1
e. other emerging and existing public health threats
1
2
identified by the State Commissioner of Health if
2
3
permitted by an order, rule, or regulation;
3
4
31. “Nonprescription drugs” means medicines or drugs which are
4
5
sold without a prescription and which are prepackaged for use by the
5
6
consumer and labeled in accordance with the requirements of the
6
7
statutes and regulations of this state and the federal government.
7
8
Such items shall also include medical and dental supplies and
8
9
bottled or nonbulk chemicals which are sold or offered for sale to
9
10
the general public if such articles or preparations meet the
10
11
requirements of the Federal Food, Drug, and Cosmetic Act, 21
11
12
U.S.C.A., Section 321 et seq.;
12
13
31. 32. “Outsourcing facility” including “virtual outsourcing
13
14
facility” means a facility at one geographic location or address
14
15
that:
15
16
a. is engaged in the compounding of sterile drugs,
16
17
b. has elected to register as an outsourcing facility,
17
18
and
18
19
c. complies with all requirements of 21 U.S.C. 353b;
19
20
32. 33. “Package” means the smallest individual saleable unit
20
21
of product for distribution by a manufacturer or repackager that is
21
22
intended by the manufacturer for ultimate sale to the dispenser of
22
23
such product. For the purposes of this paragraph, “individual
23
24
saleable unit” means the smallest container of a product introduced
24
Req. No. 705 Page 9

1
into commerce by the manufacturer or repackager that is intended by
1
2
the manufacturer or repackager for individual sale to a dispenser;
2
3
33. 34. “Person” means an individual, partnership, limited
3
4
liability company, corporation, or association, unless the context
4
5
otherwise requires;
5
6
34. 35. “Pharmacist-in-charge” or “PIC” means the pharmacist
6
7
licensed in this state responsible for the management control of a
7
8
pharmacy and all other aspects of the practice of pharmacy in a
8
9
licensed pharmacy as defined by Section 353.18 of this title;
9
10
35. 36. “Pharmacy” means a place regularly licensed by the
10
11
State Board of Pharmacy in which prescriptions, drugs, medicines,
11
12
chemicals, and poisons are compounded or dispensed or such place
12
13
where pharmacists practice the profession of pharmacy, or a pharmacy
13
14
operated by the Oklahoma Department of Veterans Affairs;
14
15
36. 37. “Pharmacy technician”, “technician”, “Rx tech”, or
15
16
“tech” means a person issued a Technician technician permit by the
16
17
State Board of Pharmacy to assist the pharmacist and perform
17
18
nonjudgmental, technical, manipulative, non-discretionary functions
18
19
in the prescription department under the immediate and direct
19
20
supervision of a pharmacist;
20
21
37. 38. “Poison” means any substance which when introduced into
21
22
the body, either directly or by absorption, produces violent,
22
23
morbid, or fatal changes, or which destroys living tissue with which
23
24
such substance comes into contact;
24
Req. No. 705 Page 10

1
38. 39. “Practice of pharmacy” means:
1
2
a. the interpretation and evaluation of prescription
2
3
orders,
3
4
b. the compounding, dispensing, administering, and
4
5
labeling of drugs and devices, except labeling by a
5
6
manufacturer, repackager, or distributor of
6
7
nonprescription drugs and commercially packaged legend
7
8
drugs and devices,
8
9
c. the participation in drug selection and drug
9
10
utilization reviews,
10
11
d. the proper and safe storage of drugs and devices and
11
12
the maintenance of proper records thereof,
12
13
e. the responsibility for advising by counseling and
13
14
providing information, where professionally necessary
14
15
or where regulated, of therapeutic values, content,
15
16
hazards, and use of drugs and devices,
16
17
f. the offering or performing of those acts, services,
17
18
operations, or transactions necessary in the conduct,
18
19
operation, management, and control of a pharmacy, or
19
20
g. the ordering, performing, and interpreting of tests
20
21
for minor, nonchronic health conditions that meet the
21
22
requirements of Section 1 of this act and the
22
23
initiation of drug therapy for minor, nonchronic
23
24
health conditions, or
24
Req. No. 705 Page 11

1
h. the provision of those acts or services that are
1
2
necessary to provide pharmaceutical care;
2
3
39. 40. “Preparation” means an article which may or may not
3
4
contain sterile products compounded in a licensed pharmacy pursuant
4
5
to the order of a licensed prescriber;
5
6
40. 41. “Prescriber” means a person licensed in this state who
6
7
is authorized to prescribe dangerous drugs within the scope of
7
8
practice of the person’s profession;
8
9
41. 42. “Prescription” means and includes any order for drug or
9
10
medical supplies written or signed, or transmitted by word of mouth,
10
11
telephone, or other means of communication:
11
12
a. by a licensed prescriber,
12
13
b. under the supervision of an Oklahoma licensed
13
14
practitioner, an Oklahoma licensed advanced practice
14
15
registered nurse Advanced Practice Registered Nurse,
15
16
or an Oklahoma licensed physician assistant, or
16
17
c. by an Oklahoma licensed wholesaler or distributor as
17
18
authorized in Section 353.29.1 of this title;
18
19
42. 43. “Product” means a prescription drug in a finished
19
20
dosage form for administration to a patient without substantial
20
21
further manufacturing, such as capsules, tablets, and lyophilized
21
22
products before reconstitution. “Product” Product does not include
22
23
blood components intended for transfusion, radioactive drugs or
23
24
biologics and medical gas;
24
Req. No. 705 Page 12

1
43. 44. “Repackager”, including “virtual repackager”, means a
1
2
person who owns or operates an establishment that repacks and
2
3
relabels a product or package for further sale or distribution
3
4
without further transaction;
4
5
44. 45. “Sterile drug” means a drug that is intended for
5
6
parenteral administration, an ophthalmic or oral inhalation drug in
6
7
aqueous format, or a drug that is required to be sterile under state
7
8
and federal law;
8
9
45. 46. “Supervising physician” means an individual holding a
9
10
current license to practice as a physician from the State Board of
10
11
Medical Licensure and Supervision, pursuant to the provisions of the
11
12
Oklahoma Allopathic Medical and Surgical Licensure and Supervision
12
13
Act, or the State Board of Osteopathic Examiners, pursuant to the
13
14
provisions of the Oklahoma Osteopathic Medicine Act, who supervises
14
15
an advanced practice registered nurse Advanced Practice Registered
15
16
Nurse as defined in Section 567.3a of this title, and who is not in
16
17
training as an intern, resident, or fellow. To be eligible to
17
18
supervise an advanced practice registered nurse Advanced Practice
18
19
Registered Nurse, such physician shall remain in compliance with the
19
20
rules promulgated by the State Board of Medical Licensure and
20
21
Supervision or the State Board of Osteopathic Examiners;
21
22
46. 47. “Supportive personnel” means technicians and auxiliary
22
23
supportive persons who are regularly paid employees of a pharmacy
23
24
24
Req. No. 705 Page 13

1
who work and perform tasks in the pharmacy as authorized by Section
1
2
353.18A of this title;
2
3
47. 48. “Third-party logistics provider” including “virtual
3
4
third-party logistics provider” means an entity that provides or
4
5
coordinates warehousing, or other logistics services of a product in
5
6
interstate commerce on behalf of a manufacturer, wholesale
6
7
distributor, or dispenser of a product but does not take ownership
7
8
of the product, nor have responsibility to direct the sale or
8
9
disposition of the product. For the purposes of this paragraph,
9
10
“third-party logistics provider” third-party logistics provider does
10
11
not include shippers and the United States Postal Service;
11
12
48. 49. “Wholesale distributor” including “virtual wholesale
12
13
distributor” means a person other than a manufacturer, a
13
14
manufacturer’s co-licensed partner, a third-party logistics
14
15
provider, or repackager engaged in wholesale distribution as defined
15
16
by 21 U.S.C. 353(e)(4) as amended by the Drug Supply Chain Security
16
17
Act;
17
18
49. 50. “County jail” means a facility operated by a county for
18
19
the physical detention and correction of persons charged with, or
19
20
convicted of, criminal offenses or ordinance violations or persons
20
21
found guilty of civil or criminal contempt;
21
22
50. 51. “State correctional facility” means a facility or
22
23
institution that houses a prisoner population under the jurisdiction
23
24
of the Department of Corrections;
24
Req. No. 705 Page 14

1
51. 52. “Unit dose package” means a package that contains a
1
2
single dose drug with the name, strength, control number, and
2
3
expiration date of that drug on the label; and
3
4
52. 53. “Unit of issue package” means a package that provides
4
5
multiple doses of the same drug, but each drug is individually
5
6
separated and includes the name, lot number, and expiration date.
6
7
SECTION 3. This act shall become effective November 1, 2025.
7
8
8
9
60-1-705 DC 1/19/2025 5:42:21 AM
9
10
10
11
11
12
12
13
13
14
14
15
15
16
16
17
17
18
18
19
19
20
20
21
21
22
22
23
23
24
24
Req. No. 705 Page 15

[DELETED:  P B G]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P f i]
[DELETED:  P]
[DELETED:  P a]
[DELETED:  P a a a]
[DELETED:  P i s S l]
[DELETED:  P o i h c]
[DELETED:  P]
[DELETED:  P t t t t t t t]
[DELETED:  P t b u b]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P D 1]